A Pivotal Phase III trial of FG001 in Aggressive Brain Cancer
Latest Information Update: 15 Jan 2024
At a glance
- Drugs FG 001 (Primary)
- Indications Glioblastoma; Glioma
- Focus Registrational; Therapeutic Use
- Sponsors FluoGuide
- 08 Jan 2024 According to a FluoGuide media release, the company plans to advance FG001 into the first clinical trial for registration of FG001 in fluorescence guided surgery (FGS) of aggressive brain cancer, based on feedback from the U.S. Food and Drug Administration (FDA).
- 08 Jan 2024 According to a FluoGuide media release, Clinical trial to be used for registration of FG001 in fluorescent guided surgery of aggressive brain cancer expected to start in 2025.
- 08 Nov 2022 According to a FluoGuide media release, A first large scale batch for FG001 has now been successfully manufactured by PolyPeptide in preparation for this study.